OOIR: Observatory of International Research

Papers

(The TQCC of Translational Neurodegeneration is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	252
Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules	244
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	158
Cellular senescence in Alzheimer’s disease: from physiology to pathology	144
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease	116
Clinical evidence of human pathogens implicated in Alzheimer’s disease pathology and the therapeutic efficacy of antimicrobials: an overview	90
Metabolic changes in an animal model of amyotrophic lateral sclerosis evaluated by [18F]-FDG positron emission tomography	84
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	70
Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases	70
Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy	69
Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment	68
The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders	63
Inhibition of lysine methyltransferase G9a/GLP reinstates long-term synaptic plasticity and synaptic tagging/capture by facilitating protein synthesis in the hippocampal CA1 area of APP/PS1 mouse mode	62
Analysis of human brain tissue derived from DBS surgery	61
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	59
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	58
Genetic spectrum and clinical features in a cohort of Chinese patients with autosomal recessive cerebellar ataxias	57
Perivascular spaces relate to the course and cognition of Huntington’s disease	56
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction	55
Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration	52
Can exercise benefits be harnessed with drugs? A new way to combat neurodegenerative diseases by boosting neurogenesis	52
Ultrasensitive detection of TDP-43 and amyloid-β protein aggregates using micelle-assisted seed amplification assay	50
Endosomal traffic disorders: a driving force behind neurodegenerative diseases	49
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	48
TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease	47

Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	45
Early life adversity as a risk factor for cognitive impairment and Alzheimer’s disease	45
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease	43
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	43
Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases	43
Updates in Alzheimer's disease: from basic research to diagnosis and therapies	41
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis	39
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	39
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	39
Circadian disruption and sleep disorders in neurodegeneration	39
p85S6K sustains synaptic GluA1 to ameliorate cognitive deficits in Alzheimer’s disease	39
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease	38
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	37
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases	37
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms	36
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	36
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	35
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	33
Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia	33
Clinical and genetic characterization of a large cohort of patients with Wilson’s disease in China	33
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease	33
Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease	32
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?	32
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	31
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	31
COVID-19 and Alzheimer’s disease: how one crisis worsens the other	31
Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes	30
Early GCase activity is a predictor of long-term cognitive decline in Parkinson’s disease	30
α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies	27
GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model	27
Cellular senescence as a key contributor to secondary neurodegeneration in traumatic brain injury and stroke	27
A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	27
Correction: Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	27
Correction: Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations	27
The microglial P2Y6 receptor as a therapeutic target for neurodegenerative diseases	26
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers	26
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	26